Results 31 to 40 of about 181,578 (308)

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. [PDF]

, 2017
BackgroundT cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined.
A Molinolo, A Stasi Di, A Thor, B Fisher, BA Irving, BL Levine, C Romeo, CC Kloss, CY Wu, D Moritz, DL Porter, DW Lee, F Guadagni, HM Finney, I Blanco, I Stancovski, J Scholler, JD Wolchok, JL Murray, JN Kochenderfer, JW Greiner, KD Griffith, L Naldini, M Hegde, M Kalos, ME Dudley, MH Finer, MH Kershaw, ML Davila, MR Lander, N Gonzales, NP Restifo, P Hwu, RA Morgan, RE Walker, RF Meredith, RP McGuinness, RT Mitsuyasu, S Guedan, SD Patel, SG Deeks, SL Maude, SV Kashmiri   +42 more
core   +1 more source

Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues ...
Alejandro Ramírez-Chacón, Alejandro Ramírez-Chacón, Sergi Betriu-Méndez, Sergi Betriu-Méndez, Ariadna Bartoló-Ibars, Ariadna Bartoló-Ibars, Azucena González, Azucena González, Azucena González, Mercè Martí, Mercè Martí, Manel Juan, Manel Juan, Manel Juan   +13 more
doaj   +1 more source

The pharmacology of second-generation chimeric antigen receptors [PDF]

Nature Reviews Drug Discovery, 2015
Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to augment their antitumour efficacy. The combined activating and co-stimulatory domains incorporated in these CARs critically determine the function, differentiation, metabolism and persistence of engineered T cells.
Sjoukje J C, van der Stegen, Mohamad, Hamieh, Michel, Sadelain   +2 more
openaire   +2 more sources

Unlocking the potential of Tregs: innovations in CAR technology

Frontiers in Molecular Biosciences, 2023
Regulatory T cells (Tregs) adoptive immunotherapy is emerging as a viable treatment option for both autoimmune and alloimmune diseases. However, numerous challenges remain, including limitations related to cell number, availability of target-specific ...
Christopher J. Requejo Cier, Nicolas Valentini, Caroline Lamarche   +2 more
doaj   +1 more source

New simplified molecular design for functional T cell receptor [PDF]

, 1993
We have produced a chimeric single-chain T cell receptor (TcR) that combines the specific antibody recognition function and TcR/CD3 signaling properties within the same polypeptide chain.
Clevers, Cosson, Eshhar, Frank, Gillis, Gunning, Hackett, Huston, Ihle, Irving, Lanzavecchia, Leo, Mosmann, Oi, Romeo, Sterz, Tada, Traunecker, Walker, Wegener, Weissman, Weissman, White, Zamoyska   +23 more
core   +1 more source

Mesothelin-targeting chimeric antigen receptor–modified T cells by transposon system suppress the growth of bile duct carcinoma

Tumor Biology, 2017
Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored.
Jie-Ying Xu, Zhen-Long Ye, Du-Qing Jiang, Jiang-Chuan He, Yong-Mei Ding, Lin-Fang Li, Sai-Qun Lv, Ying Wang, Hua-Jun Jin, Qi-Jun Qian   +9 more
doaj   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Haematologica, 2016
Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent, Richard W.J. Groen, Willy A. Noort, Maria Themeli, Jeroen J. Lammerts van Bueren, Paul W.H.I. Parren, Jürgen Kuball, Zsolt Sebestyen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Anton C.M. Martens, Henk M. Lokhorst, Tuna Mutis   +13 more
doaj   +1 more source

Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells

Frontiers in Genetics, 2020
The term cancer stem cell (CSC) starts 25 years ago with the evidence that CSC is a subpopulation of tumor cells that have renewal ability and can differentiate into several distinct linages.
Rowa Y. Alhabbab
doaj   +1 more source

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)

Mediterranean Journal of Hematology and Infectious Diseases, 2021
Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-
Eugenio Galli, Silvia Bellesi, Marcello Viscovo, Federica Sorà, Stefan Hohaus, Nicola Piccirillo, Luca Laurenti, Patrizia Chiusolo, Valerio De Stefano, Simona Sica, Gina Zini   +10 more
doaj   +1 more source